Ronald M. Evans

Salk Institute for Biological Studies

Public scientific profile · Unclaimed

Built from public scholarly sources. Expertise is inferred by ScienceWe from publications and has not been confirmed by the scientist.

Top expertise

  • Histone Deacetylase Inhibitors Research

    Strong evidence · 3 supporting papers · latest 2026

  • Pancreatic and Hepatic Oncology Research

    Strong evidence · 4 supporting papers · latest 2026

  • Mitochondrial Function and Pathology

    Strong evidence · 1 supporting paper · latest 2026

  • Adipose Tissue and Metabolism

    Solid evidence · 1 supporting paper · latest 2025

  • Epigenetics and DNA Methylation

    Solid evidence · 4 supporting papers · latest 2026

  • Pancreatitis Pathology and Treatment

    Solid evidence · 2 supporting papers · latest 2026

  • Vitamin D Research Studies

    Solid evidence · 1 supporting paper · latest 2026

  • Retinoids in leukemia and cellular processes

    Solid evidence · 2 supporting papers · latest 2026

Publications (15)

  • A phase II clinical trial of albumin-bound paclitaxel, cisplatin, gemcitabine (NABPLAGEM), and paricalcitol as neoadjuvant therapy in pancreatic cancer

    2026DOIPMID 42268676

  • Multi-layered transcriptional control of glycogen metabolism coordinates thermogenic remodeling of white adipocytes in male mice

    2025DOIPMID 41402325

  • A scalable embryonic stem cell–based platform for efficient generation of mitochondrial DNA mutant mice

    2026DOIPMID 41950089

  • HDAC inhibition sensitizes pancreatic tumors to DNA damage by global redistribution of the transcriptional machinery

    2026DOIPMID 42348617

  • Patient-derived organoids reveal ductal dysfunction and CFTR-modulator responses in chronic pancreatitis

    2026DOIPMID 42379165

  • HDAC Inhibition Sensitizes Pancreatic Tumors to DNA Damage by Global Redistribution of the Transcriptional Machinery

    2026DOIPMID 42239268

  • Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial

    2026DOIPMID 42185478

  • Targeting Wnt/β-catenin and circadian regulator restores PRC2/EZH2-controlled chromatin bivalency and suppresses cell state diversity

    2026DOIPMID 41842971

  • CA19-9 induces microenvironment remodeling in pancreatic ductal adenocarcinoma

    2026DOIPMID 42244695

  • David John “Davo” Mangelsdorf (1958–2025): A life of science, friendship, and joy

    2025DOIPMID 41405864

  • Abstract LB097: HDAC inhibition sensitizes pancreatic cancer to DNA-damaging therapies via genome-wide redistribution of transcriptional machinery

    2026DOI

  • SMRT regulation of nuclear receptors orchestrates bile acid homeostasis

    2026DOIPMID 42717237

  • CA19-9 promotes liver metastasis of pancreatic cancer through E-selectin mediated extravasation

    2026DOIPMID 41993312

  • Abstract A052: CA19-9 promotes liver metastasis of pancreatic cancer through E-selectin mediated seeding in mice

    2026DOI

  • Neutrophils preserve energy storage in sympathetically activated adipocytes

    2025DOIPMID 41372404

Organizations in sourced records

Affiliation evidence only — not confirmed current employment.

  • Salk Institute for Biological Studies

Source: OpenAlex · retrieved 2026-09-29

Are you Ronald M. Evans? Sign in to claim this profile